3 stories
Noom is the digital health platform that has spent 2025 and 2026 pivoting deeper into peptide-medicated weight loss. The most consequential 2026 move: Noom acquired Tailor Made Compounding, a licensed 503A pharmacy in 46 states that serves 400+ clinics with compounded peptides including sermorelin, GHK-Cu, and oxytocin.
The acquisition put Noom in the same competitive frame as Hims & Hers, Ro, and other telehealth platforms that have built distribution on top of the compounded-peptide channel. The April 30, 2026 FDA proposal to exclude branded GLP-1s from the 503B bulks list affects Tailor Made directly.
Stories here cover the platform moves, partnership deals, and quarterly results. See #telehealth and #compounding for related threads.
Wellness platform Noom acquired Tailor Made Compounding (TMC), a licensed 503A pharmacy operating in 46 states, marking its largest investment in healthy aging. Noom plans to expand its formulary to include peptide therapies like sermorelin and GHK-Cu alongside NAD+ and hormone treatments.
Noom acquired Tailor Made Compounding, a licensed 503A pharmacy in 46 states serving 400+ clinics, offering compounded peptides including sermorelin, GHK-Cu, and oxytocin.
Digital health companies are betting on peptides as the next big wellness category. They're banking on HHS Secretary RFK Jr. getting the FDA to lift restrictions on certain peptides.